Investing in the future of medicine

• Dina joined NeoMed in 2009. She manages NeoMed’s funds and assists with and advises on new investments for Omega. Dina has been investing in the private equity and venture capital healthcare industry since 2001. Previously at 3i in London and Index Ventures in Geneva, her recent investments including Spruce Biosciences, Attenua, Imago BioSciences, Oxular, TopiVert, Wilson Therapeutics, EUSA Pharma, Endosense and Novexel.

Dina is a member of the Venture Capital Platform Council of Invest Europe. She is a CFA charterholder and holds a Ph.D. degree in Molecular and Cellular Biology from Paris VI University, France and carried out postdoctoral research at Brown University, Providence, US, and at the Fox Chase Cancer Centre, Philadelphia, US.

Bernard joined Omega Funds in 2020. He has extensive experience in the life sciences and biotech industry, marked by a number of successful transactions involving financings and M&A. Bernard previously served as SVP and Managing Director at Sanofi Ventures, having first joined Sanofi in 2010 as Vice President, Deputy Global Head, Business Development. Over his 7-year tenure, Sanofi Ventures invested in 28 new companies and generated 14 exits (12 NASDAQ IPOs, 1 trade sale and 1 option deal).

Prior to Sanofi, Bernard held CEO, CFO and other leadership roles at Fovea Pharmaceuticals (which was sold to Sanofi in 2009 in a €370 million cash transaction), Neurotech Pharmaceuticals, Transgene (which successfully raised $100 million in a 1998 IPO on the NASDAQ/EuroNext) and Institut Mérieux (now Sanofi Pasteur).

Michelle joined Omega Funds in 2016. She has nearly 20 years of experience advising life sciences companies on private placements, public equity financing and M&A transactions. Previously, Michelle worked as Director of Corporate Finance at Third Rock Ventures, where she supported numerous portfolio companies. Prior to joining Third Rock, Michelle was Principal, Corporate Finance, at Abingworth. She was also a life sciences investment banker with Lehman Brothers International in London, JP Morgan/H&Q in New York and Morgan Stanley in Toronto and New York. Michelle has executed more than 40 equity and convertible transactions and numerous IPOs, private placements and M&A transactions for companies, including Gilead, MedImmune, Millennium, Illumina and Sepracor. Michelle graduated with an Honor’s degree in Business Administration from the Richard Ivey School of Business at the University of Western Ontario in London.

Francesco rejoined Omega Funds in 2016, where he focuses on private company investing. He is also heavily involved with Omega’s direct secondary transactions and investor relations.

Prior to joining Omega, Francesco was an Analyst at Brookside Mezzanine Partners, a $500 million mezzanine fund investing in subordinated debt and minority equity in small- to mid-size companies throughout the U.S., where he focused on due diligence, deal management, and investor relations. Concurrently, he worked for uConnect, a SaaS education technology start-up helping university career centers impact student outcomes, where he focused on fundraising, finance, and operations. Prior to Brookside and uConnect, Francesco was an Associate at Commonfund Capital (CCI), the private capital arm of the $24 billion fund of funds Commonfund, where he focused on due diligence, manager selection, investment management, and investor relations for CCI’s private equity, venture capital, and natural resources programs. He began his career at Omega, when he joined in 2008, as an Analyst. Francesco graduated cum laude from the Isenberg School of Management at the University of Massachusetts Amherst with a BBA in Finance and Operations Management. He is also a CFA charterholder, a CAIA charterholder, and a Certified FRM.

Thomas joined NeoMed in 2005. He manages NeoMed’s funds and assists with and advises on new investments for Omega.

Thomas has over 10 years of experience of venture capital investing in healthcare in Europe. Previously, he was a global biotechnology analyst for Pictet & Cie, Switzerland’s largest private bank. He was also Manager of Regulatory Affairs with worldwide responsibilities at Firmenich SA, a global leader in fragrances, flavourings and fine chemicals. Thomas holds a PhD in molecular biology from the University of Geneva, Switzerland.

Paulina joined Omega Funds in 2019. Prior to joining Omega, Paulina was on the healthcare team at Polaris Partners since 2012. Paulina is currently an observer on the board of Arrakis Therapeutics. Paulina previously served on the boards of Kala Pharmaceuticals (NASDAQ: KALA), Neuronetics (NASDAQ: STIM), Lyra Pharmaceuticals, Faraday Pharmaceuticals, Arsenal Medical and CAMP4 Therapeutics, where she was the founding CEO. Paulina completed her postdoctoral fellowship in Robert Langer’s lab in the Chemical Engineering department at the Massachusetts Institute of Technology. Paulina was the founding president of the MIT Postdoctoral Association and served on the MIT Intellectual Property Presidential Committee. Paulina completed her PhD in Molecular Medicine from the Wake Forest University School of Medicine and graduated magna cum laude from East Carolina University with a quadruple major in biochemistry, neuroscience, biology and chemistry.

Katie joined Omega Funds in 2019. She leads the firm’s communications strategy and investor relations initiatives, including marketing and fundraising. Katie is also involved in the portfolio management of public company investments.

Prior to joining Omega, Katie spent five years in equity research covering specialty pharmaceutical companies, initially as an Associate at BMO Capital Markets in New York and most recently as a Vice President at Wells Fargo Securities in New York. Katie also has an extensive journalism background, including on-air roles with an NBC-affiliate local news station and a national online news network, along with reporting/producing positions with CNBC and Bloomberg, in New York and London. Katie graduated cum laude from the School of Journalism at the University of Missouri with a Bachelor of Journalism degree. She also maintains FINRA Series 7, 63, 79, 86, and 87 licenses and is a CFA Level III Exam Candidate.

Annie joined Omega Funds in 2015. She focuses on private company investing, particularly in the areas of oncology, autoimmune and inflammatory diseases and technology platforms. She currently serves as a Director on the board of Trevi Therapeutics (NASDAQ:TRVI).

Prior to joining Omega, she spent three years at MIT’s Technology Licensing Office as a licensing associate and associate licensing officer, where she managed a portfolio of drug delivery and biotechnology inventions. Annie also worked as an independent consultant for Nelsen Biomedical, where she performed market analyses and advised clients on partnering and market entry strategies. Annie earned her PhD in Biomedical Engineering from the University of Michigan and a BS in Biomedical Engineering from the University of Virginia.

Vincent joined Omega Funds in 2014 and subsequently joined NeoMed in 2017. He focuses on European investments in the areas of oncology, autoimmune and inflammatory diseases and medtech.

Previously, Vincent worked with Sectoral Asset Management, a healthcare institutional investor, as a Partner for private investments. From 2000 to 2006 he was a research fellow at the University of Geneva, studying the molecular basis of brain function, and also acted as Sectoral Asset Management’s Chief Scientific Officer during this period. Previously, he worked at Pictet Bank as a research analyst for biotechnology equities and as a co-manager of the Pictet Biotech Fund, a $2 billion listed investment vehicle. Vincent trained as a postdoctoral fellow in Geneva (Hoffman-La-Roche and Human Frontier Science Program fellow) and at the National Cancer Institute in Bethesda, MD. He completed a Certificate in International Finance and Global Markets at the Georgetown University School of Business and holds an MS in Computational Sciences, an MS in Molecular Biology, and a PhD in Molecular Biology, all from the University of Geneva.

Philipp joined Omega Funds in 2018 and assists with the accounting and financial reporting for the firm’s management company and fund vehicles.

Before joining Omega, Philipp was responsible for all operations and financial reporting at a family office. Prior to his role at the family office, he worked in public accounting at PwC, focusing primarily on alternative investment clients. Philipp received his BA in Business Administration from Furman University and holds a MSA/MBA from Northeastern University. He is also licensed as a Certified Public Accountant in the Commonwealth of Massachusetts and is a CFA Exam Level III Candidate.

Deirdre joined Omega Funds in 2019 from Catabasis Pharmaceuticals, where she served as Chief Legal Officer since February 2018 and Principal Financial Officer and Treasurer since April 2016. Previously, she served as Catabasis’ Senior Vice President and General Counsel from November 2015 to February 2018. Prior to joining Catabasis, Deirdre served as General Counsel at Advanced Technology Ventures, from January 2006 to October 2015, and at Lightstone Ventures, from its founding in January 2012 until October 2015. Prior to ATV and Lightstone, she was an investment officer at BancBoston Ventures and Deputy General Counsel at BancBoston Capital. Deirdre started her law career with, and later became a Partner in, Goodwin Procter’s corporate department.

Deirdre holds a J.D. from Boston College Law School and a B.S. in Finance from the Boston College School of Management.

Gilchrist joined Omega Funds in 2018 and assists with the accounting and financial reporting for the firm’s management company and fund vehicles.

Prior to joining Omega, Gilchrist worked in similar roles at Vista Equity Partners and Benefit Street Partners, while also having earlier experience working in public accounting at PwC. Gilchrist received both his BS in Business Administration and his MSA from the University of Rhode Island.

Mark joined Omega Funds in 2010. He manages the firm’s regulatory compliance program and assists with the firm’s financial operations and reporting.

Prior to joining Omega, Mark worked for three years as the Accounting Manager at Schooner Capital, a private investment firm in Boston. Prior to Schooner, he worked for several years in hedge fund administration at Bisys. Mark received his BS in Accounting from Plymouth State University and his MBA from Suffolk University. He is also licensed as a Certified Public Accountant in the Commonwealth of MA.

Pennylynn joined Omega Funds in 2017. She provides administrative support to Otello Stampacchia and has over nine years of experience in sales and administration. Prior to joining Omega, Pennylynn worked at Black Box Network Services where she supported two executives, a sales team of 20, and worked as the primary lead for pricing on all high value RFPs. She also worked as an independent consultant, specialty in project management and data integrity. Pennylynn graduated Cum Laude from the University of Missouri Saint Louis and holds a BS in Business Administration.

Estelle joined NeoMed in 2018. She provides administrative support to Claudio Nessi, Vincent Ossipow & Thomas Goebel. Prior to joining NeoMed, Estelle worked as an executive assistant at Kellogg Company. Prior working for Kellogg, Estelle worked as an administrative assistant at Procter & Gamble. Estelle graduated from Lycée Jean-Piaget in Neuchâtel, business school in 2002.

Caroline joined Omega Funds in 2019. She serves as Omega Funds’ receptionist while providing general administrative support to the team. Prior to joining Omega, Caroline worked as a teacher at The New England Center for Children where she implemented behavioral and educational programs for young adults with autism. Caroline graduated from Saint Joseph’s University in 2018 and holds a BS in Interdisciplinary Health Services with concentrations in Healthcare Ethics and Psychology.

Ellissa joined Omega Funds in 2017. She provides administrative support to Michelle Doig. Prior to joining Omega, Ellissa worked as a Program Manager for the U.S. Air Force. Prior to working for the Air Force, Ellissa taught second grade for three years. Ellissa graduated Magna Cum Laude from the University of Vermont and holds a BS in Elementary Education with a concentration in Communication Sciences.

Heather joined Omega Funds in 2018. She provides general administrative support to the investment and finance teams. Prior to joining Omega, Heather worked as a program manager at Horizons for Homeless Children helping to oversee a network of more than 1000 volunteers. Heather earned her MPA from Bridgewater State University in 2017 after completing her BA in Political Science.

Erik founded NeoMed in 1997 and served as its Managing Partner until 2015. He will continue to manage NeoMed’s funds and is available to advise on certain investments for Omega Fund V. He has over 30 years’ experience of venture capital investing in Europe and the United States, the last 20 of which have been in the healthcare industry. Previously, Erik was Chairman of NeoMed AS, an investment advisory firm specialized in the healthcare industry, and President of Origo Ventures AS, a Norwegian private equity firm. Erik is a co-founder and former chairman of the Norwegian Venture Capital Association. Erik holds a Master’s degree of Science in Management from the Graduate School of Business, Stanford University, and a PhD in Organic Chemistry from the University of Oslo, Norway.

Charles (Charlie) McDermott joined Omega Funds in January 2019. Charlie has more than 24 years of experience in the life sciences industry and has held roles of increasing responsibility in drug discovery, regulatory affairs, corporate development, commercial planning, and executive management. Charlie also currently serves as Director at Primmune Therapeutics. Previously, Charlie served as President, Chief Business Officer, and a member of the board of directors of Impact Biomedicines, Inc. Impact was acquired by Celgene in 2018 for $1.1 billion upfront and up to $7 billion overall, if all contingent payments are realized. Prior to joining Impact, Charlie was President and Chief Business Officer of Kala Pharmaceuticals, Inc. Before Joining Kala, Charlie worked at Allergan as Vice President, Global Business Development for the Eye Care and Drug Delivery business units. Before Joining Allergan, Charlie was Associate Director of Business Development at deCODE genetics and before that he worked at Pfizer/Agouron in drug discovery and regulatory affairs. Charlie has a B.A. in biochemistry and molecular biology from UC Santa Cruz, a M.A. in molecular, cellular, and developmental biology from UC Santa Barbara, and a MBA from the University of San Diego.

Gary D. Glick joined Omega Funds in February 2020. Gary is co-founder and Executive Chairman of IFM Therapeutics. Gary started his career as a faculty member at the University of Michigan in Ann Arbor, where he is currently the Werner E. Bachmann emeritus professor of chemistry. While at Michigan, Gary founded Lycera Corp, serving first as President, then as CSO. Under his direction, Lycera initiated six discovery programs, partnered three of these programs with Merck & Co. in deals collectively valued at over $600M, and advanced two programs into clinical testing. After leaving Lycera in 2015, Gary founded First Wave Bio, a clinical stage company focused on novel, cost-effective treatments for inflammatory bowel disease, and then IFM Therapeutics, to develop modulators of innate immune system proteins as treatments for cancer and inflammatory diseases. In 2017, IFM sold two of the company’s cancer assets to BMS for more than $2.3B, while retaining a portfolio of drug candidates for inflammatory and autoimmune diseases. In 2019, Gary led the sale of IFM’s NLRP3 subsidiary, IFM Tre, to Novartis in a deal valued at $1.6B.
Gary obtained a Ph.D. degree in organic chemistry from Columbia University and was an NIH postdoctoral fellow at Harvard University. He is the author of over 100 papers and the inventor on 33 issued U.S. patents and is the recipient of numerous awards recognizing his scientific contributions and accomplishments as a life science executive.